Side effects as predictors of drug response in obsessive-compulsive disorder

Journal of Clinical Psychopharmacology

Volumn 19, Issue 5, 1999, Pages 459-465

  Ackerman, Deborah L ^a   Greenland, Sander ^a   Bystritsky, Alexander ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; FLUOXETINE; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HAMILTON SCALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; NAUSEA; OBSESSION; ONSET AGE; PREDICTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEROTONINERGIC SYSTEM; SIDE EFFECT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANXIETY; CLOMIPRAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EJACULATION; FEMALE; FLUOXETINE; HUMANS; LIBIDO; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; ORGASM; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 0032825330     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199910000-00010     Document Type: Article

References (32)

1. Pigott TA, Pato MT, Bernstein SE, Grover GN, Hill JL, Tolliver TJ, Murphy DL. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results. Arch Gen Psychiatry 1990;47:926-32.
2. Freeman CP, Trimble MR, Deakin JF, Stokes TM, Ashford JJ. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatry 1994;55:301-54.
3. Koran LM, McElroy SL, Davidson JR, Rasmussen SA, Hollander E, Jenike MA. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. J Clin Psychopharmacol 1996;16:121-9.
4. Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. Br J Psychiatry 1996;169:468-74.
5. Lopez-Ibor JJ Jr, Saiz J, Cottraux J, Note I, Vinas R, Bourgeois M, Hernandez M, Gomez-Perez JC. Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder. Eur Neuropsychopharmacol 1996;6:111-8.
6. Milanfranchi A, Ravagli S, Lensi P, Marazziti D, Cassano GB. A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 1997;12:131-6.
7. Bisserbe JC, Lane R, Flament MF. Double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder. Eur Psychiatry 1997;12:82-93.
8. Jenike MA, Baer L, Greist JH. Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy. J Clin Psychopharmacol 1990; 10:122-4.
9. Stein DJ, Spadaccini E, Hollander E. Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacol 1995;10:11-8.
10. Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC. Efficacy and tolerability of serotonin transport inhibitors. Arch Gen Psychiatry 1995;52:53-60.
11. Piccinelli M, Pini S, Bellantuono C, Wilkinson G. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry 1995;166:424-43.
12. Flament MF, Bisserbe JC. Pharmacologic treatment of obsessive-compulsive disorder: comparative studies. J Clin Psychiatry 1997; 58[suppl 12]:18-22.
13. Abramowitz JS. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol 1997;65:44-52.
14. White K, Kando J, Park T, Waternaux C, Brown WA. Side effects and the "blindability" of clinical drug trials. Am J Psychiatry 1992;149:1730-1.
15. Bystritsky A, Waikar SV. Inert placebo versus active medication. Patient blindability in clinical pharmacological trials. J Nerv Ment Dis 1994;182:485-7.
16. Hermesh H, Aizenberg D, Weizman A, Lapidot M, Munitz H. Clomipramine-induced urinary dysfunction in an obsessive-compulsive adolescent. Drug Intell Clin Pharm 1987;21:877-9.
17. Hollander E, DeCaria CM, Schneier FR, Schneier HA, Liebowitz MR, Klein DF. Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. J Clin Psychiatry 1990;51: 119-23.
18. Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991;48:730-8.
19. Ackerman DL, Greenland S, Bystritsky A, Katz RJ. Relationship between early side effects and therapeutic effects of clomipramine therapy in OCD. J Clin Psychopharmacol 1996;16:324-8.
20. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Psychol 1967;6:278-96.
21. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-11.
22. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry 1989;46:1012-6.
23. Ackerman DL, Greenland S, Bystritsky A, Morgenstern H, Katz RJ. Predictors of treatment response in obsessive-compulsive disorder: multivariate analyses from a multicenter trial of clomipramine. J Clin Psychopharmacol 1994;14:247-54.
24. Ackerman DL, Greenland S, Bystritsky A. A receiver-operator characteristic (ROC) analysis of response to clomipramine therapy. Psychopharmacol Bull 1996;32:157-65.
25. Tollefson GD, Rampey AH, Potvin JH, Jenike MA, Rush JA, Dominguez RA, Koran LM, Shear MK, Goodman W, Genduso LA. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994;51:559-67.
26. Ackerman DL, Greenland S, Bystritsky A. Clinical characteristics of responders to fluoxetine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1998;18:185-92.
27. Pigott TA. OCD: where the serotonin selectivity story begins. J Clin Psychiatry 1996;57[suppl 6]:11-20.
28. Bystritsky A, Ackerman DL, Pasnau RO. Low dose desipramine treatment of cocaine-related panic attacks. J Nerv Mental Dis 1991;179:755-8.
29. Ford CV. The somatizing disorders. Psychosomatics 1986;27: 327-37.
30. Kellner R. Somatization: theories and research. J Nerv Mental Dis 1990;178:150-60.
31. Tangrea JA, Adrianza ME, Helsel WE. Risk factors for the development of placebo adverse reactions in a multicenter clinical trial. Ann Epidemiol 1994;4:327-31.
32. Davis C, Ralevski E, Kennedy SH, Neitzert C. The role of personality factors in the reporting of side effect complaints to moclobemide and placebo: a study of healthy male and female volunteers. J Clin Psychopharmacol 1995;15:347-52.